Amphastar Pharmaceuticals Free Cash Flow 2012-2024 | AMPH

Amphastar Pharmaceuticals free cash flow from 2012 to 2024. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
Amphastar Pharmaceuticals Annual Free Cash Flow
2023 145.34
2022 65.57
2021 70.54
2020 23.41
2019 0.21
2018 -8.37
2017 4.11
2016 17.18
2015 -5.32
2014 0.55
2013 12.74
2012 -25.31
2011 8.42
2009
Amphastar Pharmaceuticals Quarterly Free Cash Flow
2024-09-30 155.73
2024-06-30 109.56
2024-03-31 46.50
2023-12-31 145.34
2023-09-30 130.92
2023-06-30 76.77
2023-03-31 30.91
2022-12-31 65.57
2022-09-30 56.65
2022-06-30 41.90
2022-03-31 44.63
2021-12-31 70.54
2021-09-30 36.98
2021-06-30 41.63
2021-03-31 15.21
2020-12-31 23.41
2020-09-30 15.85
2020-06-30 12.11
2020-03-31 -6.74
2019-12-31 0.21
2019-09-30 2.97
2019-06-30 23.65
2019-03-31 -18.35
2018-12-31 -8.37
2018-09-30 -8.55
2018-06-30 -11.70
2018-03-31 -3.98
2017-12-31 4.11
2017-09-30 4.46
2017-06-30 13.40
2017-03-31 15.13
2016-12-31 17.18
2016-09-30 8.51
2016-06-30 10.70
2016-03-31 9.98
2015-12-31 -5.32
2015-09-30 -4.48
2015-06-30 -3.74
2015-03-31 -2.84
2014-12-31 0.55
2014-09-30 -2.94
2014-06-30 -12.36
2014-03-31 -10.06
2013-12-31 12.74
2013-09-30 8.13
2013-06-30 11.95
2013-03-31 -4.92
2012-12-31 -25.31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $2.186B $0.644B
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.395B 6.36
Dr Reddy's Laboratories (RDY) India $11.853B 22.68
BridgeBio Pharma (BBIO) United States $4.426B 0.00
Bausch Health Cos (BHC) Canada $2.931B 2.13
Supernus Pharmaceuticals (SUPN) United States $2.000B 27.23
Taysha Gene Therapies (TSHA) United States $0.506B 35.29
Personalis (PSNL) United States $0.245B 0.00
Assembly Biosciences (ASMB) United States $0.096B 0.00
Sol-Gel Technologies (SLGL) Israel $0.015B 0.00
Evoke Pharma (EVOK) United States $0.006B 0.00
Teligent (TLGT) United States $0.000B 0.00